Developer docs
API playgroundTry for free, no card

Search company profiles

Kronos Bio

Full company profile

uuid0002iyd

Namestring
Kronos Bio
Websiteurl
kronosbio.com
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSan Mateo, United States
HQ citystring
San Mateo
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology drug development, acute myeloid leukemia treatment, SYK inhibitor therapeutics, clinical-stage biopharmaceuticals, targeted cancer therapies
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Social media profiles2 records
Revenue model1 record
1Drug Development Pipeline
TypeLicensing Royalties
Description

Pre-commercial biopharmaceutical company developing lanraplenib through clinical trials. Revenue generation would occur upon FDA approval and commercialization, likely through pharmaceutical product sales or potential licensing/partnership arrangements.

openpr.com
Cost components4 values
Personnel, Technology or R&D, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Kronos Bio is a clinical-stage biopharmaceutical company developing first-in-class therapies that modulate historically recalcitrant cancer targets. Its lead asset, lanraplenib, is a proprietary SYK (spleen tyrosine kinase) inhibitor being advanced in clinical trials for patients with relapsed/refractory acute myeloid leukemia (AML). The company has no commercialized products and focuses entirely on research, clinical development, and eventual commercialization or out-licensing of its drug candidate.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Kronos Bio is a pharmaceutical company developing lanraplenib, a SYK inhibitor drug candidate in clinical trials for relapsed/refractory acute myeloid leukemia (AML). The company's product pipeline consists of this single drug candidate representing a therapeutic approach targeting the SYK signaling pathway.

Product and service1 record
1Lanraplenib
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Global pharmaceutical company with active AML programs, including CALQUENCE (acalabrutinib) in hematologic malignancies and investigational AML assets. Comparable as a broad incumbent with overlapping oncology development and significant commercial reach.

2Syros Pharmaceuticals
TypeDirect peer
Description

Clinical-stage biopharmaceutical company focused on hematologic malignancies and AML, developing novel small molecule therapies targeting gene expression. Highly comparable to Kronos Bio as a similarly-sized, similarly-staged oncology therapeutics developer with hematology pipeline assets.

TypeBroad incumbent
Description

Large pharmaceutical company with venetoclax (Venclexta), a leading Bcl-2 inhibitor approved for AML in combination regimens. Represents the established standard-of-care competitor that Kronos Bio's lanraplenib would need to differentiate against.

4Bristol-Myers Squibb
TypeBroad incumbent
Description

Major pharmaceutical company with a substantial AML franchise including azacitidine-based combinations and an active pipeline of hematology assets. Comparable as a broad incumbent with overlapping AML development and commercialization capabilities.

TypeDirect peer
Description

Clinical-stage precision oncology company developing small molecule therapeutics for hematologic malignancies and solid tumors. Comparable to Kronos Bio as a similarly-staged small-cap oncology developer with targeted small molecule assets.

TypeBroad incumbent
Description

Large biopharmaceutical company with magrolimab, an anti-CD47 antibody in development for AML and MDS, representing a novel immuno-oncology approach to hematologic malignancies. Comparable as a broad incumbent investing heavily in next-generation AML therapeutics.

7Rigel Pharmaceuticals
TypeDirect peer
Description

Commercial and clinical-stage company that developed fostamatinib, a SYK inhibitor approved for immune thrombocytopenia. Directly comparable to Kronos Bio through shared SYK kinase pharmacology and small molecule hematology/oncology focus.

TypeEmerging player
Description

Clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that target DNA damage response pathways. Comparable to Kronos Bio as a small-cap, clinical-stage oncology developer with single-asset or focused pipeline exposure.

TypeBroad incumbent
Description

Global pharmaceutical company that commercializes gilteritinib (Xospata), an FLT3 inhibitor approved for relapsed/refractory AML. Represents another entrenched large-pharma competitor in the same AML indication.

TypeDirect peer
Description

Clinical-stage biotechnology company developing targeted therapeutics for hematologic malignancies and solid tumors. Comparable to Kronos Bio as a similarly-staged clinical developer focused on oncology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors17 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Kronos Bio

Oncology Therapeuticskronosbio.com

Kronos Bio firmographics

Firmographics
Name
Kronos Bio
Website
https://kronosbio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Where Kronos Bio is headquartered

Location

Headquarters

HQ city
San Mateo
HQ country
United States
HQ region
North America

Markets served

Kronos Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Others

Revenue model

  1. Drug Development Pipeline: Pre-commercial biopharmaceutical company developing lanraplenib through clinical trials. Revenue generation would occur upon FDA approval and commercialization, likely through pharmaceutical product sales or potential licensing/partnership arrangements.

Kronos Bio product offering

Product offering

Core offering

Kronos Bio is a clinical-stage biopharmaceutical company developing first-in-class therapies that modulate historically recalcitrant cancer targets. Its lead asset, lanraplenib, is a proprietary SYK (spleen tyrosine kinase) inhibitor being advanced in clinical trials for patients with relapsed/refractory acute myeloid leukemia (AML). The company has no commercialized products and focuses entirely on research, clinical development, and eventual commercialization or out-licensing of its drug candidate.

Product overview

Kronos Bio is a pharmaceutical company developing lanraplenib, a SYK inhibitor drug candidate in clinical trials for relapsed/refractory acute myeloid leukemia (AML). The company's product pipeline consists of this single drug candidate representing a therapeutic approach targeting the SYK signaling pathway.

Differentiator

Problem solved

Functional benefit

Products and services

  • Lanraplenib

Companies that use Kronos Bio

Customer profile

Segments1 record

Ideal customer profiles1 record

Kronos Bio technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Kronos Bio partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

Kronos Bio competitors and assessment

Company assessment

Broad incumbents

  • AstraZeneca: Global pharmaceutical company with active AML programs, including CALQUENCE (acalabrutinib) in hematologic malignancies and investigational AML assets. Comparable as a broad incumbent with overlapping oncology development and significant commercial reach.
  • AbbVie: Large pharmaceutical company with venetoclax (Venclexta), a leading Bcl-2 inhibitor approved for AML in combination regimens. Represents the established standard-of-care competitor that Kronos Bio's lanraplenib would need to differentiate against.
  • Bristol-Myers Squibb: Major pharmaceutical company with a substantial AML franchise including azacitidine-based combinations and an active pipeline of hematology assets. Comparable as a broad incumbent with overlapping AML development and commercialization capabilities.
  • Gilead Sciences: Large biopharmaceutical company with magrolimab, an anti-CD47 antibody in development for AML and MDS, representing a novel immuno-oncology approach to hematologic malignancies. Comparable as a broad incumbent investing heavily in next-generation AML therapeutics.
  • Astellas Pharma: Global pharmaceutical company that commercializes gilteritinib (Xospata), an FLT3 inhibitor approved for relapsed/refractory AML. Represents another entrenched large-pharma competitor in the same AML indication.

Direct peers

  • Syros Pharmaceuticals: Clinical-stage biopharmaceutical company focused on hematologic malignancies and AML, developing novel small molecule therapies targeting gene expression. Highly comparable to Kronos Bio as a similarly-sized, similarly-staged oncology therapeutics developer with hematology pipeline assets.
  • Kura Oncology: Clinical-stage precision oncology company developing small molecule therapeutics for hematologic malignancies and solid tumors. Comparable to Kronos Bio as a similarly-staged small-cap oncology developer with targeted small molecule assets.
  • Rigel Pharmaceuticals: Commercial and clinical-stage company that developed fostamatinib, a SYK inhibitor approved for immune thrombocytopenia. Directly comparable to Kronos Bio through shared SYK kinase pharmacology and small molecule hematology/oncology focus.
  • Curis: Clinical-stage biotechnology company developing targeted therapeutics for hematologic malignancies and solid tumors. Comparable to Kronos Bio as a similarly-staged clinical developer focused on oncology.

Emerging players

  • Aprea Therapeutics: Clinical-stage biopharmaceutical company focused on developing novel cancer therapeutics that target DNA damage response pathways. Comparable to Kronos Bio as a small-cap, clinical-stage oncology developer with single-asset or focused pipeline exposure.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights5 records

Customer concentration

Kronos Bio social profiles

Digital presence

Kronos Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Kronos Bio leadership team

Management profile

Number of profiles

Profiles1 record

Kronos Bio funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors17 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Kronos Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kronos Bio

What does Kronos Bio do?

Kronos Bio is a clinical-stage biopharmaceutical company developing first-in-class therapies that modulate historically recalcitrant cancer targets. Its lead asset, lanraplenib, is a proprietary SYK (spleen tyrosine kinase) inhibitor being advanced in clinical trials for patients with relapsed/refractory acute myeloid leukemia (AML). The company has no commercialized products and focuses entirely on research, clinical development, and eventual commercialization or out-licensing of its drug candidate.

When was Kronos Bio founded?

Kronos Bio was founded in 2017. It employs 51 to 100 people.

Where is Kronos Bio based?

Kronos Bio is headquartered in San Mateo, United States, in the North America region.

How does Kronos Bio make money?

One revenue line is on record: drug Development Pipeline.

Who are Kronos Bio's main competitors?

Broad incumbents on record are AstraZeneca, AbbVie, Bristol-Myers Squibb, Gilead Sciences and Astellas Pharma. Direct peers are Syros Pharmaceuticals, Kura Oncology, Rigel Pharmaceuticals and Curis. Aprea Therapeutics is listed as an emerging player.

Does Kronos Bio have an API?

No public API is recorded for Kronos Bio.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestThe High-Stakes Gamble: CVRs in Distressed Biotech M&A and What Investors Need to KnowConcentra Biosciences acquires distressed biotechs like Elevation Oncology and Kronos Bio using contingent value rights (CVRs), paying minimal cash and deferring payouts to future asset sales. The strategy minimizes upfront costs but carries risks from litigation and market volatility, making CVRs a high-risk, high-reward instrument for investors.PR NewswireSHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Kronos Bio, Inc. - KRONMonteverde & Associates PC is investigating Kronos Bio's proposed merger with Concentra Biosciences, which would pay $0.57 per share plus a contingent value right. The firm, a class action securities firm, is seeking to recover money for shareholders.BenzingaKronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic OverhaulKronos Bio, Inc. has appointed Deborah Knobelman as President and Interim CEO, effective December 3, 2024, replacing Norbert Bischofberger who will step down but remain on the board as an advisor. The company announced plans to lay off approximately 83% of its workforce by the end of the year as part of cost reduction strategies while exploring potential business combinations or divestitures of its preclinical assets. KRON stock has lost over 31% in the past year, with shares trading higher by 6.47% premarket following the announcement.GlobeNewswireKronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple MyelomaKronos Bio will present preclinical data on its p300 KAT inhibitor KB-9558 for multiple myeloma at the ASH Annual Meeting on December 9, 2024. The data shows a strong IRF4-p300 interaction in multiple myeloma, which the company says is targetable. The poster will be available on the company website.GlobeNewswireKronos Bio to Present Data at the EORTC-NCI-AACR Symposium that Supports p300 KAT Inhibition in HPV-Driven TumorsKronos Bio will present preclinical data on its p300 KAT inhibitor KB-9558 for HPV-driven tumors at the EORTC-NCI-AACR Symposium in Barcelona, Oct. 23-25, 2024. The data show KB-9558 selectively inhibits HPV oncoproteins E6 and E7, driving anti-tumor effects and p53 reactivation. The company aims to provide targeted therapies for HPV-driven cancers.BenzingaCancer Player Kronos Bio To Stop Lanraplenib Combo Therapy Blood Cancer StudyKronos Bio Inc announced it will discontinue development of lanraplenib in combination with gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia after reviewing Phase 1b data from 24 patients across four dose cohorts, with no complete responses observed despite some blast reductions. The company also disclosed a new development candidate, KB-9558, targeting p300 for multiple myeloma, and provided an update that KB-0742 cleared the 80 mg dose in its ongoing Phase 1/2 solid tumor trial, with data expected in mid-2024. Kronos Bio is implementing restructuring measures including a 19% workforce reduction to extend its cash runway into 2026.trib.alKronos Bio’s stock rallies after announcing drug-discovery deal with RocheKronos Bio's stock rose 25% in premarket trading after announcing a drug-discovery deal with Genentech. Roche will pay $20 million upfront, with milestone payments up to $554 million. The company's stock has fallen 86.4% over the past year.GlobeNewswireKronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in OncologyKronos Bio announced a discovery collaboration with Genentech to develop small-molecule drugs targeting transcription factors in oncology. The deal includes a $20 million upfront payment and up to $554 million in milestone and royalty payments. Kronos Bio will lead discovery to a preclinical point, after which Genentech gains exclusive rights.GlobeNewswireKronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in OncologyKronos Bio announced a discovery collaboration with Genentech to develop small-molecule drugs targeting transcription factors in oncology. The deal includes a $20 million upfront payment and up to $554 million in milestone payments, with Kronos leading discovery to a preclinical point.BioSpaceKronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742Kronos Bio announced it will focus on lanraplenib and KB-0742, discontinuing the Phase 3 entospletinib trial for newly diagnosed NPM1-mutated AML. The company has $270.3 million in cash, extending its runway into Q2 2025. It plans to report KB-0742 trial data in Q4 2022.